Author Interviews, Lipids, NEJM, Neurological Disorders, Stroke / 18.11.2019
Lower LDL Cholesterol Linked to Reduced Risk of Recurrent Stroke
MedicalResearch.com Interview with:
Pierre Amarenco, MD
Professor and Chairman
Paris University, Paris, France
INSERM
Department of Neurology and Stroke Centre
Bichat Hospital
Paris, France
MedicalResearch.com: What is the background for this study?
Response: The rationale of the Treat Stroke to target trial was that after we published the SPARCL trial in 2006 (atorvastatin 80 mg/day vs placebo in patients with stroke) which showed a 16% relative risk reduction of recurrent stroke, we performed several pre specified and post hoc analyses, showing that in SPARCL patients randomized with "atherosclerotic disease" the risk reduction for the primary endpoint was much higher (33%), and in in patients achieving a LDL cholesterol of less than 70 mg/dL as compared to those achieving a LDL cholesterol 100 mg/dL or higher, the risk reduction was 28%.
Therefore to confirm this findings, we designed the TST trial, which was an investigator initiated trial funded by the french ministry of health, and enrolled patients with an ischemic stroke due to atherosclerotic stenosis and randomized them to either a target LDL cholesterol of less than 70 mg/dL or a target LDL cholesterol of 90 to 110 mg/dL. To achieve these goals, the investigators could use any statin available on the market, and titrate the dosage of the statin to get to the assigned target. They could also use ezetimibe on top of statin therapy if a high dosage of statin was not sufficient to get to the target level assigned by randomization. (more…)